DK2945968T3 - Antistoffer der binder til jagged 1 - Google Patents
Antistoffer der binder til jagged 1 Download PDFInfo
- Publication number
- DK2945968T3 DK2945968T3 DK14701426.0T DK14701426T DK2945968T3 DK 2945968 T3 DK2945968 T3 DK 2945968T3 DK 14701426 T DK14701426 T DK 14701426T DK 2945968 T3 DK2945968 T3 DK 2945968T3
- Authority
- DK
- Denmark
- Prior art keywords
- jagged
- antibodies binding
- antibodies
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1300706.7A GB201300706D0 (en) | 2013-01-15 | 2013-01-15 | Antibody |
PCT/GB2014/050104 WO2014111704A1 (en) | 2013-01-15 | 2014-01-15 | Antibodies that bind to jagged 1 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2945968T3 true DK2945968T3 (da) | 2019-05-20 |
Family
ID=47758013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14701426.0T DK2945968T3 (da) | 2013-01-15 | 2014-01-15 | Antistoffer der binder til jagged 1 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9725518B2 (da) |
EP (1) | EP2945968B1 (da) |
JP (1) | JP6416117B2 (da) |
CA (1) | CA2897869A1 (da) |
DK (1) | DK2945968T3 (da) |
ES (1) | ES2724244T3 (da) |
GB (1) | GB201300706D0 (da) |
WO (1) | WO2014111704A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2685424T3 (es) | 2014-02-12 | 2018-10-09 | F. Hoffmann-La Roche Ag | Anticuerpos anti-Jagged1 y procedimientos de uso |
EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
PL234632B1 (pl) | 2016-03-02 | 2020-03-31 | Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk | Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania |
WO2017189705A1 (en) * | 2016-04-26 | 2017-11-02 | Temple University-Of The Commonwealth System Of Higher Education | Dll4-expressing cells and vaccine using the same |
JOP20190259A1 (ar) * | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
EP3438128B1 (en) * | 2017-08-04 | 2020-05-20 | Alzheimur 2012 S.L. | Anti-presenilin antibody for use in the prevention and/or treatment of cancer |
EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
US20200237909A1 (en) * | 2017-10-12 | 2020-07-30 | The Trustees Of Princeton University | Methods of treating or preventing breast cancer metastases using antibodies to jagged1 and chemotherapeutic agents |
AU2019205279A1 (en) * | 2018-01-08 | 2020-07-30 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008140826A1 (en) | 2007-05-15 | 2008-11-20 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US8945569B2 (en) * | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
PE20150643A1 (es) * | 2012-06-22 | 2015-05-29 | Cytomx Therapeutics Inc | Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos |
-
2013
- 2013-01-15 GB GBGB1300706.7A patent/GB201300706D0/en not_active Ceased
-
2014
- 2014-01-15 JP JP2015553162A patent/JP6416117B2/ja not_active Expired - Fee Related
- 2014-01-15 DK DK14701426.0T patent/DK2945968T3/da active
- 2014-01-15 CA CA2897869A patent/CA2897869A1/en not_active Abandoned
- 2014-01-15 ES ES14701426T patent/ES2724244T3/es active Active
- 2014-01-15 WO PCT/GB2014/050104 patent/WO2014111704A1/en active Application Filing
- 2014-01-15 EP EP14701426.0A patent/EP2945968B1/en active Active
- 2014-01-15 US US14/761,062 patent/US9725518B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016504420A (ja) | 2016-02-12 |
EP2945968B1 (en) | 2019-04-10 |
JP6416117B2 (ja) | 2018-10-31 |
US20160108128A1 (en) | 2016-04-21 |
ES2724244T3 (es) | 2019-09-09 |
US9725518B2 (en) | 2017-08-08 |
GB201300706D0 (en) | 2013-02-27 |
EP2945968A1 (en) | 2015-11-25 |
CA2897869A1 (en) | 2014-07-24 |
WO2014111704A1 (en) | 2014-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2992100T3 (da) | Agrokemiske sammensætninger omfattende antistoffer, der binder til sphingolipider | |
CY2023021I1 (el) | Αντισωματα που δεσμευουν την il-23 | |
DK2895503T3 (da) | Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin | |
DK2970464T3 (da) | Anti-lag-3-bindende proteiner | |
FI11677U1 (fi) | Uusiutuva hiilivetykoostumus | |
DK3336106T3 (da) | Anti-fcrh5-antistoffer | |
DK2945968T3 (da) | Antistoffer der binder til jagged 1 | |
DK2935329T3 (da) | Antistoffer, der binder til human programmeret dødsligand 1 (pd-l1) | |
DK3708583T3 (da) | Ikke-fucosylerede anti-fgfr2iiib-antistoffer | |
DK3350223T3 (da) | Antistoffer, der binder specifikt til tl1a | |
FI11676U1 (fi) | Uusiutuva hiilivetykoostumus | |
BR112014016855A2 (pt) | soluções aglutinantes | |
DK3521312T3 (da) | Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom | |
HK1217500A1 (zh) | 特異性結合 的抗體 | |
DK3456743T3 (da) | Oncostatin m-receptorantigenbindingsproteiner | |
CL2016001147A1 (es) | Anticuerpos específicos para fcrn. | |
DK3038633T3 (da) | Stabile polypeptider der binder til human komplement c5 | |
ZA201505125B (en) | Hydraulic binder | |
DK3065774T3 (da) | Anti-CCL17-antistoffer | |
HK1218921A1 (zh) | 特異性結合 的抗體 | |
CL2013003511S1 (es) | Carpeta | |
TH1401005566A (th) | องค์ประกอบสารยึดสำหรับการเตรียมแบบหล่อ | |
TH1401005842A (th) | แอนติบอดีต่อ siglec-15 ที่ดัดแปลง cdr | |
TH1401007552A (th) | แฟ้มใบหลวม (loose leaf binder) | |
GB201300998D0 (en) | Binder Clip |